The Quality Control Assessment of Commercially Available Coenzyme Q10–Containing Dietary and Health Supplements in Japan

Aikkarach Kettawan1, Chitsopa Kunthida1, Takayuki Takahashi1,2, Takeo Kishi1, Jun Chikazawa3, Yuka Sakata1, Eiji Yano3, Kazuo Watabe1, Yorihiro Yamamoto5, and Tadashi Okamoto1,2*

1Laboratory of Biochemistry, Department of Health Sciences and Social Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 651-2180, Japan
2Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 651-2180, Japan
3Shiseido Pharmaceutical Co. Ltd., Tokyo105-0021, Japan
4Pharmaceutical Research Laboratories, Shiseido Research Center, Yokohama 236-8643, Japan
5School of Bionics, Tokyo University of Technology, Hachioji 192-0982, Japan

Received 27 December 2006; Accepted 19 January, 2007

Summary Coenzyme Q10 (CoQ10) has been widely commercially available in Japan as a dietary and health supplement since 2001 and is used for the prevention of lifestyle-related diseases induced by free radicals and aging. We evaluated CoQ10 supplements to ensure that these supplements can be used effectively and safely. Commercially available products were selected and assessed by the quality control tests specified in the Japanese Pharmacopoeia XV. When the disintegration time of CoQ10 supplements was measured, a few tested supplements did not completely disintegrate even after incubation in water for an hour at 37°C. In the content test, many samples were well controlled. However, a few supplements showed low recovery rates of CoQ10 as compared to manufacturer’s indicated contents. Among soft capsule and liquid supplements, the reduced form of CoQ10 (H2CoQ10), as well as the oxidized form, was detected by HPLC with electrochemical detector. The results for experimental formulated CoQ10 supplements demonstrated that H2CoQ10 was produced by the interaction of CoQ10 with vitamins E and/or C. From these results, we concluded that quality varied considerably among the many supplement brands containing CoQ10. Additionally, we also demonstrated that H2CoQ10 can be detected in some foods as well as in CoQ10 supplements.

Key Words: coenzyme Q10, ubiqinol-10, quality control, dietary and health supplement, food

Introduction

It is well known that coenzyme Q (CoQ) serves as an essential carrier for electron transport and proton translocation in the mitochondrial respiratory chain [1]. Besides its role in electron-transfer reactions, CoQ serves as a free radical scavenger, thereby preventing oxidative damage in the human body. Several researchers have pointed out that the reduced form of CoQ10 (H2CoQ10) is an efficient scavenger of lipid radicals and inhibitors of lipid peroxidation in low-density lipoprotein [2, 3], biomembrane [4], and liposomes [5, 6]. CoQ in the bodies of human beings is thought to be provided by both dietary intake, from foods or dietary supplements [7, 8], and de novo biosynthesis [9, 10]. Therefore, decreases in the biosynthesis or intake of CoQ10 might affect
the physiological action of CoQ\textsubscript{10}. In fact, decreased serum levels of CoQ\textsubscript{10} were observed in patients undergoing total parenteral nutrition therapy without dietary intake \cite{11}, and in patients \cite{12, 13} and animals \cite{14, 15} receiving HMG-CoA reductase inhibitor (statin) administration.

CoQ\textsubscript{10} was introduced into clinical therapy in 1974 in Japan. Its generic name is ubidecarenone. Many clinical trials showed that oral administration to patients was effective for mild congestive heart failure symptoms such as edema, lung congestion, and swollen liver. On the basis of these clinical findings, CoQ\textsubscript{10} was classified in the group of cardiovascular drugs for metabolic disturbances. In 1991, CoQ\textsubscript{10}, whose generic name is ubiquinone-10, was also made available as an over-the-counter drug in pharmacies.

While sales of dietary and health supplement products have been rapidly increasing in Japan, it is vital to supply quality-controlled products for consumers. In 2001, the Ministry of Health, Labour and Welfare in Japan permitted the use of CoQ\textsubscript{10} as a food additive as long as no claims were made about its pharmacological effectiveness and application. Currently, it is estimated that more than 200 kinds of CoQ\textsubscript{10}-containing dietary and health supplements (CoQ\textsubscript{10} supplements), produced by more than 100 different manufacturers, are available. In particular, CoQ\textsubscript{10} supplements are used for the prevention of lifestyle-related diseases induced by free radicals and aging. However, the products may vary in quality. Because CoQ\textsubscript{10} has a rather complicated chemical structure and possesses several physical properties, such as low melting point, hydrophobic nature, and light sensitivity, that do not favor large-scale commercial production, highly sophisticated techniques should be employed at all production stages to obtain a satisfactory product \cite{16}. Moreover, many Japanese CoQ\textsubscript{10} supplements also contain other components, e.g., vitamins, minerals, amino acids, antioxidative compounds, and enzymes, in the same tablet, soft capsule, or other product. Therefore, the chemical stability of CoQ\textsubscript{10} supplements is also an important point to be considered.

In this study, we evaluated the quality of commercially available CoQ\textsubscript{10} supplements to ensure that these supplements can be used effectively and safely. In addition, to investigate the distribution of CoQ\textsubscript{10} in foods from a nutritional point of view, we also measured both CoQ\textsubscript{10} and H\textsubscript{2}CoQ\textsubscript{10} contents in selected foods.

### Materials and Methods

#### Reagents

Authentic CoQ homologues from CoQ\textsubscript{7} to CoQ\textsubscript{11} were kindly supplied by Nisshin Pharma Inc., Tokyo. High performance liquid chromatography (HPLC) solvents and ethanol were purchased (HPLC grade) from Wako Pure Chemical Industries, Ltd., Osaka, Japan. All other chemicals used were of analytical grade, available from commercial suppliers.

#### CoQ\textsubscript{10} supplements

CoQ\textsubscript{10} supplements were commercially purchased from pharmacies, health food stores, department stores, convenience stores, and sport goods shops in the Kobe city area. Forms tested in this study included tablet (TB), hard capsule (HCP), soft capsule (SCP), granule (GN), liquid (LQ), jelly (JL), and inclusion complex with \(\gamma\)-dextrin (ICD). The quality control tests of CoQ\textsubscript{10} supplements were completed within 6 months before the product’s consume-by date. CoQ\textsubscript{10} supplements obtained for testing were preserved in tight, light-resistant containers at room temperature until the quality control tests were conducted.

#### Experimental manufacturing preparations for SCPs, a LQ, and an HCP of “Formulas 1 to 5”

Experimental manufacturing products for 3 SCP forms, a LQ form, and an HCP form of formulas 1 to 5 were kindly provided by Shiseido Medical, Co., Ltd., Tokyo, Japan. The detailed formulas of their components are shown in Table 1.

#### Quality control tests

#### Disintegration test—This test was performed using the apparatus (Model TMB-81, Toyama Sangyo Co., Ltd., Osaka, Japan) and test conditions specified in the Japanese Pharmacopoeia XV (J.P.XV). Water and the first (pH 1.2) and the second (pH 6.8) fluids of the J.P.XV method were used as the immersion solution at 37 ± 2°C. The time required for each TB, HCP, and SCP to completely disintegrate was recorded, and the mean disintegration time was calculated. Complete disintegration is defined by the J.P.XV as that state in which any residue of the unit, except fragments of insoluble coating or capsule shell, remaining

| Table 1. Experimental formulas of CoQ\textsubscript{10} supplement forms of soft capsule, liquid, and hard capsule |
|---------------------------------------------------------------|
| Contents | “Formula 1” | “Formula 2” | “Formula 3” | “Formula 4” | “Formula 5” |
| Intake form | Soft capsule | Soft capsule | Soft capsule | Liquid | Hard capsule |
| Based Oil | Safflower oil | Safflower oil | Olive oil | — | — |
| CoQ\textsubscript{10} | 30 mg | 10 mg | 30 mg | 30 mg | 30 mg |
| Vitamin E | 10 mg | 30 mg | 10 mg | 10 mg | 10 mg |
| Vitamin C | 30 mg | — | 30 mg | 30 mg | 30 mg |

Vol. 41, No. 2, 2007
on the screen (0.25–0.31 mm) of the test apparatus is a soft mass having no palpably firm core.

**Content test**—All procedures for the content test of CoQ<sub>10</sub> supplements were carried out in the dark.

i) **Pre-preparation of CoQ<sub>10</sub> supplements**

TB and ICD products were crushed carefully in a mortar to obtain a homogenous fine powder. This powder was transferred completely to a 50-ml brown volumetric flask, and about 30 ml of ethanol was added to the flask.

HCP and SCP products were carefully opened, the contents were transferred completely to a brown 50-ml volumetric flask, and about 30 ml of ethanol was added to the flask. If ethanol-insoluble contents and/or fragments were observed, these were sonicated on ice for 1 min with output 3 to 5 (Ultrasonic Distruptor, Model UR-200P, Tomy Seiko Co, Ltd., Tokyo, Japan).

In the case of LQ products, an aliquot of 5 ml of drink solution was pipetted into a 50-ml brown volumetric flask directly, and about 30 ml of ethanol was added to the flask. For JL and GN products, an equivalent of 5 mg was weighed accurately and dissolved in 10 ml of water and about 20 ml of ethanol in a mortar to obtain a homogenous solution. The solution was completely transferred to a brown 50-ml volumetric flask.

ii) **Preparation of CoQ<sub>10</sub> supplements**

After the ethanol solution was prepared as described above, it was incubated for 10 min at 50°C and allowed to stand for 10 min at room temperature. Then, the ethanol solution was added to the flask again to scale up to 50 ml. The solution was filtered with filter paper (No. 3) and diluted with ethanol to adjust to a 10 µg/ml CoQ<sub>10</sub>-containing ethanol solution. Finally, except for SCP products, an aliquot of 10 µl of the ethanol solution was injected into the column to determine H<sub>2</sub>CoQ<sub>10</sub>.

In the case of SCP products only, an aliquot of 0.5 ml of 10 µg/ml CoQ<sub>10</sub>-containing ethanol solution was pipetted into a brown glass-stoppered centrifuged tube, and then 0.5 ml of distilled water, 1.5 ml of ethanol, and 5 ml of n-hexane were added in turn. The mixture was shaken vigorously reciprocally at a rate of 80 times per minute for 10 min and centrifuged at 500 g for 10 min. This extraction procedure was repeated three times. Subsequently, the combined n-hexane layer was concentrated in vacuo under a stream of nitrogen. The resulting residue was dissolved in 0.5 ml of ethanol, and an aliquot of 10 µl of the ethanol solution was injected into the column to determine H<sub>2</sub>CoQ<sub>10</sub>.

Separately, an aliquot of 10 µl of 0.25% sodium borohydride solution (0.25 mg/ml water) was added to 0.4 ml of the ethanol and the mixture allowed to stand for 10 min at room temperature. An aliquot of 10 µl of the solution was injected into the column to determine total CoQ<sub>10</sub>, the sum of reduced and oxidized CoQ<sub>10</sub>.

iii) **HPLC conditions for determination of CoQ<sub>10</sub> and H:CoQ<sub>10</sub>**

The content of CoQ<sub>10</sub> supplements was determined by an HPLC method with electrochemical detection (ECD), as previously described [17]. Authentic CoQ homologues from CoQ<sub>1</sub> to CoQ<sub>10</sub> were prepared by dissolution in ethanol to yield concentrations of 10 µg/ml. Authentic CoQ homologues were freshly prepared from the corresponding CoQ, adding 25 µg of sodium borohydride (10 µl of a 0.25% solution of sodium borohydride in water) to give a concentration of 1 µg/ml prior to HPLC-ECD analysis.

**Food samples**

Food samples were obtained from local food stores or supermarkets in the Kobe city area. All food items were analyzed raw, without freezing. In some cases, samples of the same food were collected on separate days.

**Measurement of CoQ homologue contents in foods**

Food samples were homogenized with distilled water at 4°C using a Polytron homogenizer (Type PT 10/35; Kinematica, Lucerne, Switzerland) at a setting of 7 to 30 seconds. The final volume of the homogenate was adjusted so as to contain about 1 to 2 µg of H:CoQ<sub>10</sub>. An aliquot of 0.5 ml of the homogenate was pipetted into a brown glass-stoppered centrifuged tube, and then 2 ml of ethanol and 5 ml of n-hexane were added. The solution was extracted as described above for SCP products, and the contents of H:CoQs and CoQs were determined by HPLC-ECD [17].

**Results**

**Internal profile for SCP forms of CoQ<sub>10</sub> supplements**

Among CoQ<sub>10</sub> supplements, SCP is the most common commercially available intake form in Japan. According to the United States Pharmacopoeia, SCPs (sometimes called soft gelatin capsules or softgels) are filled with liquid contents in most cases. Typically, CoQ<sub>10</sub> is dissolved or suspended in a liquid vehicle such as vegetable oil or the lower-molecular-weight polyethylene glycols.

First, we assessed the internal profile of different SCP CoQ<sub>10</sub> supplement products. Most samples showed the typical internal profile of SCPs. However, as shown in Fig. 1, in a few SCPs, CoQ<sub>10</sub> crystallized itself inside and existed in the solid state but not the lipid-soluble form. Moreover, a certain SCP did not show the uniform distribution of CoQ<sub>10</sub> in the capsule.

**Disintegration tests for TB, HCP, SCP, and ICD forms of CoQ<sub>10</sub> supplements**

According to the disintegration test specified in the J.P.XV, TB supplements should disintegrate with water as the immersion fluid within 30 min after operating the apparatus. For both HCP and SCP supplements, the time limit is 20 min. Although ICD is the inclusion complex form of CoQ<sub>10</sub> and γ-
dextrin, the disintegration time is not specified by J.P.XV.

When we measured the disintegration time of 2 kinds of CoQ10-containing over-the-counter (OTC) drugs as controls, their disintegration times were 3.8 min for OTC-TB and 4.6 min for OTC-SCP, respectively. OTC drugs were well controlled and met the necessary requirements specified in the J.P.XV (Table 2).

For CoQ10 supplements, as shown in Table 2, the disintegration time was 3.2 min to >60 min for TBs, 3.2 min to 23.8 min for HCPs, 5.6 min to >60 min for SCPs, and 8.8 min to 32.5 min for ICDs; considerable differences were observed among the many supplements. In particular, the disintegration time of about half of the SCPs was more than 60 min. Among the different forms of CoQ10 supplements, the disintegration performance of ICDs was not always faster than that of other forms. Moreover, as tested supplements might be enteric-coated tablets, we also carried out the disintegration tests again for the first fluid, simulated gastric fluid (pH 1.2), and the second fluid, simulated intestinal fluid (pH 6.8). However, the results did not differ from those of water as the immersion fluid.

Content tests for CoQ10 supplements

Although the J.P.XV specifies the HPLC-UV method as the identification and content test for ubidecarenone, we applied the HPLC-ECD method as described in Materials and Methods instead because this method can measure both the reduced and oxidized forms of CoQ10 and shows higher sensitivity than the HPLC-UV method does.

Of course, the content of the over-the-counter drugs used as controls was well controlled within an extremely limited range (99–100%). Most CoQ10 supplements showed a content value of more than 80%. However, a few supplements exhibited low recovery rates of CoQ10 as compared to manufacturers’ indicated contents. Moreover, in several SCP and LQ products, H-CoQ10 as well as CoQ10 was detected. Interestingly, in LQ-6, as shown in Table 3, CoQ10 was expressed as means ± SD (n = 6).

Table 2. The disintegration time of CoQ10 supplements, tablets, hard capsules, soft capsules, and inclusion complex with γ-dextrin

| Samples* | Disintegration Time (min) |
|----------|--------------------------|
|          | Water (pH 1.2, J.P.XV)   | First fluid (pH 6.8, J.P.XV) |
| OTC-TB   | 3.8 ± 0.2                | 4.1 ± 0.4                      | 6.0 ± 0.4 |
| OTC-SCP  | 4.6 ± 0.1                | 6.8 ± 0.1                      | 9.8 ± 0.5 |
| TB-1     | 11.3 ± 0.9               | 16.5 ± 0.6                     | 11.1 ± 0.7 |
| TB-2     | 3.2 ± 0.4                | 3.6 ± 1.0                      | 2.4 ± 0.1 |
| TB-3     | 10.7 ± 0.4               | 12.8 ± 0.6                     | 13.1 ± 0.3 |
| TB-4     | 11.1 ± 0.1               | 12.1 ± 0.1                     | 13.4 ± 0.1 |
| TB-5     | >60                      | >60                            | >60       |
| TB-6     | 55.2 ± 0.9               | 56.4 ± 0.4                     | 55.9 ± 0.8 |
| TB-7     | 4.6 ± 0.6                | 3.3 ± 0.0                      | 4.1 ± 0.8 |
| TB-8     | 31.5 ± 2.6               | 32.1 ± 13.1                    | 33.7 ± 3.9 |
| TB-9     | 23.4 ± 0.7               | 32.8 ± 0.5                     | 21.4 ± 0.4 |
| TB-10    | 11.8 ± 3.2               | 11.8 ± 1.9                     | 14.8 ± 4.2 |
| TB-11    | 17.5 ± 2.8               | 19.6 ± 1.3                     | 16.5 ± 2.0 |
| TB-12    | >60                      | >60                            | >60       |
| TB-13    | 18.3 ± 0.2               | 18.6 ± 0.5                     | 18.8 ± 0.6 |
| TB-14    | 56.7 ± 1.3               | 53.4 ± 0.8                     | 58.7 ± 1.6 |
| TB-15    | 19.6 ± 1.4               | 18.9 ± 1.5                     | 18.7 ± 1.6 |
| TB-16    | 9.3 ± 1.0                | 11.3 ± 0.3                     | 11.6 ± 0.5 |
| TB-17    | 18.8 ± 1.0               | 18.6 ± 0.8                     | 25.1 ± 1.9 |
| HCP-1    | 6.9 ± 1.9                | 7.2 ± 1.5                      | 17.6 ± 0.4 |
| HCP-2    | 10.8 ± 0.6               | 9.9 ± 0.3                      | 11.9 ± 0.7 |
| HCP-3    | 3.2 ± 0.2                | 4.0 ± 0.4                      | 3.6 ± 0.3 |
| HCP-4    | 23.8 ± 3.0               | 22.5 ± 3.8                     | 13.9 ± 0.9 |
| HCP-5    | 4.9 ± 0.9                | 3.2 ± 0.1                      | 5.3 ± 0.9 |
| SCP-1    | 10.2 ± 1.0               | 12.9 ± 1.0                     | 11.2 ± 1.0 |
| SCP-2    | 5.6 ± 0.2                | 5.6 ± 0.5                      | 10.7 ± 0.5 |
| SCP-3    | 47.2 ± 1.5               | 54.9 ± 2.8                     | 57.2 ± 0.9 |
| SCP-4    | >60                      | >60                            | >60       |
| SCP-5    | >60                      | 44.0 ± 2.5                     | 52.7 ± 2.0 |
| SCP-6    | >60                      | >60                            | >60       |
| SCP-7    | >60                      | >60                            | >60       |
| SCP-8    | 41.0 ± 0.9               | 40.7 ± 2.5                     | 32.6 ± 1.9 |
| SCP-9    | 19.0 ± 1.5               | 21.5 ± 0.5                     | 13.8 ± 0.9 |
| SCP-10   | >60                      | >60                            | >60       |
| SCP-11   | 14.8 ± 0.7               | 16.9 ± 1.5                     | 14.0 ± 1.6 |
| SCP-12   | >60                      | >60                            | >60       |
| SCP-13   | 11.4 ± 0.7               | 7.8 ± 0.3                      | 8.0 ± 0.7 |
| ICD-1    | 32.5 ± 3.4               | 30.8 ± 2.7                     | 41.6 ± 2.1 |
| ICD-2    | 29.9 ± 2.1               | 41.3 ± 1.1                     | 28.1 ± 1.5 |
| ICD-3    | 12.1 ± 0.8               | 15.6 ± 1.9                     | 11.6 ± 0.9 |
| ICD-4    | 30.0 ± 2.2               | 29.8 ± 0.7                     | 31.4 ± 2.4 |
| ICD-5    | 26.4 ± 3.3               | 36.4 ± 2.7                     | 25.1 ± 2.8 |
| ICD-6    | 8.8 ± 0.7                | 12.1 ± 0.9                     | 7.6 ± 0.6 |

*OTC, over-the-counter drug; TB, tablet; HCP, hard capsule; SCP, soft capsule; ICD, inclusion complex with γ-dextrin. Data are expressed as means ± SD (n = 6).
Table 3. Content test of CoQ\textsubscript{10} supplements, tablets, hard capsules, soft capsules, liquids, jellies, granules, and inclusion complex with \(\gamma\)-dextrin

| CoQ\textsubscript{10}-supplements* | Labeled CoQ\textsubscript{10} | \(\text{H}_2\text{CoQ}_{10}\) (%)** | Total CoQ\textsubscript{10} (%)*** |
|-----------------------------------|-------------------------------|---------------------------------|---------------------------------|
| OTC-TB                            | 10                            | ND****                          | 100.5 ± 0.1 (100)               |
| OTC-SCP                           | 10                            | ND                              | 99.4 ± 0.2 (99)                 |
| TB-1                              | 10                            | ND                              | 9.6 ± 0.3 (96)                  |
| TB-2                              | 6.3                           | ND                              | 3.4 ± 0.1 (54)                  |
| TB-3                              | 11.1                          | ND                              | 9.4 ± 0.5 (85)                  |
| TB-4                              | 1.7                           | ND                              | 1.6 ± 0.1 (94)                  |
| TB-5                              | 5                             | ND                              | 4.6 ± 0.2 (92)                  |
| TB-6                              | 16.7                          | ND                              | 17.2 ± 0.4 (103)                |
| TB-7                              | 10                            | ND                              | 9.3 ± 0.4 (93)                  |
| TB-8                              | 60                            | ND                              | 55.6 ± 1.4 (93)                 |
| TB-9                              | 20                            | ND                              | 20.0 ± 0.5 (100)                |
| TB-10                             | 0.34                          | ND                              | 0.4 ± 0.01 (118)                |
| TB-11                             | 3.75                          | ND                              | 3.7 ± 0.3 (99)                  |
| TB-12                             | 0.83                          | ND                              | 0.9 ± 0.1 (108)                 |
| HCP-1                             | 90                            | ND                              | 92.3 ± 0.5 (103)                |
| HCP-2                             | 80                            | ND                              | 4.2 ± 0.1 (5)                   |
| HCP-3                             | 30                            | ND                              | 28.7 ± 1.4 (96)                 |
| HCP-4                             | 60                            | ND                              | 59.3 ± 1.3 (99)                 |
| HCP-5                             | 30                            | ND                              | 30.8 ± 0.9 (103)                |
| SCP-1                             | 33.3                          | 5.8 ± 0.5 (17)                  | 33.8 ± 1.4 (101)                |
| SCP-2                             | 30                            | 14.1 ± 1.0 (46)                 | 30.6 ± 0.9 (102)                |
| SCP-3                             | 30                            | 7.0 ± 0.8 (22)                  | 31.0 ± 1.2 (103)                |
| SCP-4                             | 30                            | 13.5 ± 0.4 (44)                 | 31.1 ± 0.7 (104)                |
| SCP-5                             | 30                            | 13.7 ± 0.7 (52)                 | 26.4 ± 1.0 (88)                 |
| SCP-6                             | 35                            | 1.6 ± 0.5 (4)                   | 35.8 ± 0.8 (102)                |
| SCP-7                             | 30                            | 1.8 ± 0.03 (6)                  | 28.0 ± 0.6 (94)                 |
| SCP-8                             | 30                            | 25.3 ± 0.7 (88)                 | 28.8 ± 0.6 (96)                 |
| SCP-9                             | 150                           | 6.2 ± 0.4 (5)                   | 120.8 ± 3.8 (80)                |
| SCP-10                            | 30                            | 1.4 ± 0.1 (4)                   | 30.7 ± 0.3 (102)                |
| SCP-11                            | 30                            | 3.8 ± 0.7 (12)                  | 30.7 ± 0.9 (102)                |
| SCP-12                            | 50                            | ND                              | 49.6 ± 1.0 (99)                 |
| SCP-13                            | 30                            | ND                              | 31.4 ± 0.4 (104)                |
| SCP-14                            | 30                            | 5.9 ± 0.7 (19)                  | 31.0 ± 0.5 (103)                |
| SCP-15                            | 10                            | ND                              | 10.1 ± 0.1 (101)                |
| SCP-16                            | 10                            | ND                              | 10.0 ± 0.1 (100)                |
| SCP-17                            | 10                            | 1.1 ± 0.2 (14)                  | 8.0 ± 0.6 (80)                  |
| SCP-18                            | 30                            | 5.2 ± 0.4 (16)                  | 31.4 ± 0.4 (105)                |
| SCP-19                            | 30                            | 2.6 ± 0.7 (9)                   | 30.4 ± 0.6 (101)                |
| SCP-20                            | 45                            | 3.9 ± 0.2 (8)                   | 46.5 ± 0.7 (103)                |
| SCP-21                            | 15                            | 8.0 ± 0.5 (53)                  | 14.9 ± 0.6 (99)                 |
| SCP-22                            | 30                            | 3.4 ± 0.2 (12)                  | 27.2 ± 0.9 (91)                 |
| SCP-23                            | 20                            | 0.9 ± 0.1 (4.2)                 | 20.2 ± 1.1 (101)                |
| SCP-24                            | 60                            | ND                              | 58.0 ± 4.1 (97)                 |
| SCP-25                            | 0.25                          | 0.04 ± 0.1 (16)                 | 0.2 ± 0.1 (96)                  |
| LQ-1                              | 40                            | ND                              | 41.4 ± 1.9 (104)                |
| LQ-2                              | 30                            | ND                              | 31.7 ± 1.4 (106)                |
| LQ-3                              | 30                            | ND                              | 32.5 ± 0.3 (108)                |
| LQ-4                              | 1                             | ND                              | 1.0 ± 0.03 (100)                |
| LQ-5                              | 50                            | 12.3 ± 2.4 (24)                 | 52.1 ± 0.8 (104)                |
| LQ-6                              | —                             | 5.2 ± 0.1 (—)                   | 5.2 ± 0.1 (—)                   |
| JL-1                              | 30                            | ND                              | 29.3 ± 0.1 (98)                 |
| JL-2                              | 50                            | ND                              | 61.5 ± 4.6 (123)                |
| GN-1                              | 30                            | ND                              | 28.5 ± 0.3 (95)                 |
| GN-2                              | 30                            | ND                              | 30.4 ± 0.2 (101)                |
| GN-3                              | 30                            | ND                              | 30.2 ± 0.2 (101)                |
| GN-4                              | 30                            | ND                              | 30.1 ± 0.1 (100)                |
| ICD-1                             | 3.75 as ICD                    | ND                              | 1.0 ± 0.01 (27)                 |
| ICD-2                             | 84                            | ND                              | 10.4 ± 0.3 (12)                 |
| ICD-3                             | 18                            | 2.0 ± 0.6 (50)                  | 3.9 ± 0.72 (22)                 |
| ICD-4                             | 100                           | ND                              | 21.8 ± 1.4 (22)                 |
| ICD-5                             | 12.5 as ICD                    | ND                              | 0.9 ± 0.1 (7)                   |
| ICD-6                             | 100                           | ND                              | 22.8 ± 0.1 (23)                 |

*OTC, over-the-counter drug; TB, tablet; HCP, hard capsule; SCP, soft capsule; LQ, liquid; JL, jelly; GN, granule; ICD, inclusion complex with \(\gamma\)-dextrin. Data are expressed as mean ± SD (n = 6).

**\(\text{H}_2\text{CoQ}_{10}/\text{total CoQ}_{10}\) (sum of CoQ\textsubscript{10} and H\textsubscript{2}CoQ\textsubscript{10}) × 100.

***\(\text{CoQ}_{10}\) (total CoQ\textsubscript{10} + H\textsubscript{2}CoQ\textsubscript{10}) × 100.

****Not detected.
recovered entirely as the reduced form, H:CoQ10.

ICD is the inclusion complex form of CoQ10 and γ-dextrin. The purposes of developing this inclusion complex with CoQ10 seem to be reduction of instability to light and enhancement of bioavailability. However, the manufacturer’s indicated contents were mentioned and listed on the package only as “CoQ10 inclusion complexes with γ-dextrin.” Thus, the CoQ10 content of the product was uncertain. As shown in Table 3, we estimated that the inclusion ratio of CoQ10 to γ-dextrin in the tested ICD will be in the range from 5% to 30%.

H:CoQ10 production in the SCP and LQ forms of CoQ10 supplements

We recognized that all CoQ10 supplements in which H:CoQ10 was detected contained vitamin E (α-tocopherol) and/or vitamin C (ascorbic acid). Therefore, we presumed that H:CoQ10 might be produced by the interaction of CoQ10 with vitamin E and/or vitamin C. To confirm this possibility, we prepared the experimental formulas listed in Table 1.

As shown in Fig. 2, co-existence of CoQ10 and vitamin E and/or vitamin C produced reduction of CoQ10 to H:CoQ10 in SCPs and a LQ. The content ratio of vitamin E to CoQ10 was also important. The existence of safflower oil in SCPs was also an essential condition for production of H:CoQ10 from CoQ10 in SCPs. In particular, a LQ form of CoQ10 that co-existed with vitamin E and vitamin C exhibited a high ratio of the reduced form to total CoQ10 in a time-dependent manner. In an HCP, however, the reduction of CoQ10 to H:CoQ10 was not observed even if CoQ10 co-existed with vitamin E and C.

Discussion

Although CoQ10 supplements have not been required to meet the same rigorous product quality performance standards as medicines do, impaired product performance, such as failure to disintegrate in the gastrointestinal tract, might limit the absorption of CoQ10. However, standardized guidelines and methods for assessing the quality control of dietary and health supplements have not been established in Japan. So, we applied the Japanese Pharmacopoeial Convention General Tests to evaluate the quality of CoQ10 supplements in this study.

Externally administered CoQ10 appears to be converted to H:CoQ10 in the human body and then to act as an antioxidant against lipid peroxidation. In fact, a CoQ10 supplement given to a human increases the serum level of H:CoQ10 as well as CoQ10 [18]. The enzymes responsible for the reduction of CoQ10 to H:CoQ10 have been reported to be not only mitochondrial respiratory enzymes but also NADPH-CoQ reductase [19–21], NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) [22, 23], thioredoxin reductase [24], and lipoamide dehydrogenase [25, 26]. CoQ in the human body is thought to be provided by both dietary intake from foods and/or dietary supplements and biosynthesis de novo.

In this study, we tested two quality control tests, disintegration and content tests. The disintegration profile and content test are thought to be essential parameters relative to absorption and intake efficacy. Many commercially available CoQ10 supplements in Japan were well controlled and met the requirements specified by J.P.XV. However, a few products exhibited insufficient quality performance. In particular, the disintegration of many SCPs required more than 60 min. The gelatin shell of an SCP is somewhat thicker than that of an HCP shell and is plasticized by the addition of a polyol such as sorbitol or glycerol. The ratio of dry plasticizer to dry gelatin determines the hardness of the shell and may be varied to accommodate environmental conditions as well as the nature of the contents. Therefore, the disintegration time of SCPs may have a higher score than that of HCPs. In this study, we demonstrated that the quality
of the many supplement products containing CoQ₁₀ in Japan varies considerably, and thus, we recommend introducing simple quality control tests for CoQ₁₀ supplements.

Among CoQ₁₀ supplements, in SCPs and LQs, H₂CoQ₁₀ as well as CoQ₁₀ was detected by the HPLC-ECD method. The results for experimentally formulated CoQ₁₀ supplements suggested that H₂CoQ₁₀ was produced by the interaction of CoQ₁₀ with vitamins E and/or C. Moreover, although H₂CoQ₁₀ is unstable when exposed to air, and can easily be oxidized into oxidized CoQ, chemically unstable H₂CoQ₁₀ is thought to exist in the body to serve as an antioxidant. Recently, Yan et al. have reported [27] that dietary supplementation with H₂CoQ₁₀ decreased the degree of senescence in middle-aged SAMP1 mice. H₂CoQ₁₀ produced by the interaction of CoQ₁₀ with vitamins E and/or C, therefore, may exert beneficial effects in the human body.

Many investigators have reported that exogenous CoQ₁₀ exhibits useful health effects. If humans consume H₂CoQ₁₀ as well as CoQ₁₀ in meals every day, foods containing H₂CoQ₁₀ and CoQ₁₀ might have some physiological activities. Therefore, it is important to investigate the distribution of these substances in foods. Some investigators have reported the CoQ homologue contents in foods. However, they could not analyze reduced forms of CoQ homologues because of the HPLC-UV method and insufficient sensitivity. In our study, we measured the distribution of both CoQ₁₀ and H₂CoQ₁₀ in food items. The results clarify that humans consume not only CoQ₁₀ but also H₂CoQ₁₀ from foods. In other words, the present study confirms the human intake of H₂CoQ₁₀ in daily foods and dietary CoQ₁₀ supplements.

Acknowledgment

This work was supported in part by a Grant-in-Aid for Scientific Research (No. 16500429) from the Ministry of Education, Science and Culture, Japan, and a Grant-in-Aid for Health Science Research as well as a Grant-in-Aid for Cooperative Research (A) from Kobe Gakuin University, Japan. This research was carried out in Coenzyme Q₁₀ Biofunctional Research Center endowed by Shiseido Pharmaceutical Co. Ltd., Tokyo, Japan.

References

[1] Crane, F.L., Hatefi, Y., Lester, R.L., and Widmer, C.: Isolation of a quinine from beef heart mitochondria. Biochim. Biophys. Acta, 25, 220–221, 1957.
[2] Frei, B., Kim, M.C., and Ames, B.N.: Ubiquinol-10 is

J. Clin. Biochem. Nutr.
an effective lipid-soluble antioxidant at physiological concentrations. *Proc. Natl. Acad. Sci. USA*, **87**, 4879–4883, 1990.

[3] Stocker, R., Bowry, V.W., and Frei, B.: Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. *Proc. Natl. Acad. Sci. USA*, **88**, 1646–1650, 1991.

[4] Kagan, V.E., Serbinova, E.A., Koyanova, G.M., Kitanova, S.A., Tyurin, V.A., Stoytchev, T.S., Quinn, P.J., and Packer, L.: Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes. *Free Radic. Biol. Med.*, **9**, 117–126, 1990.

[5] Yamamoto, Y., Komuro, E., and Niki, E.: Antioxidant activity of ubiquinol in solution and phosphatidylcholine liposome. *J. Nutr. Sci. Vitaminol.*, **36**, 505–511, 1990.

[6] Landi, L., Cabrini, L., Fiorentini, D., Stefanelli, C., and Pedulli, G.F.: The antioxidant activity of ubiquinol-3 in homogenous solution and in liposomes. *Chem. Phys. Lipids*, **61**, 121–130, 1992.

[7] Kamei, M., Fujita, T., Kanbe, T., Sasaki, K., Oshiba K., Otani, S., Matsui-Yuasa, I., and Morisawa, S.: The distribution and content of ubiquinone in foods. *Int. J. Vitam. Nutr. Res.*, **56**, 57–63, 1986.

[8] Weber, C., Bysted, A., and Hølmer, G.: The coenzyme Q10 content of the average Danish diet. *Int. J. Vitam. Nutr. Res.*, **67**, 123–129, 1996.

[9] Szkopinska, A.: Ubiquinone. biosynthesis of quinine ring and its isoprenoid side chain. Intracellular localization. *Acta Biochim. Pol.*, **47**, 496–480, 2000.

[10] Crane, F.L.: Biochemical functions of coenzyme Q10. *J. Am. Coll. Nutr.*, **20**, 591–598, 2001.

[11] Okamoto, T., Fukui, K., Nakamoto, M., Kishi, T., Kanamori, R., Kataoka, K., Nishii, S., Kishi, H., Hiraoka, E., and Okada, A.: Serum levels of coenzyme Q10 and lipids in patients during total parenteral nutrition. *J. Nutr. Sci. Vitaminol.*, **32**, 1–12, 1986.

[12] Folkers, K., Langsjoen, P., Willis, R., Richardson, P., Xia, L.J., Ye, C.Q., and Tamagawa, H.: Lovastatin decreases coenzyme Q levels in humans. *Proc. Natl. Acad. Sci. USA*, **87**, 8931–8934, 1990.

[13] Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccilioli, L., Caputo, S., Greco, A.V., and Littarru, G.P.: Evidence of plasma CoQ10–lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. *J. Clin. Pharmacol.*, **33**, 226–229, 1993.

[14] Willis, R.A., Folkers, K., Tucker, J.L., Ye, C.Q., Xia, L.J., and Tamagawa, H.: Lovastatin decreases coenzyme Q levels in rats. *Proc. Natl. Acad. Sci. USA*, **87**, 8928–8930, 1990.

[15] Kettawan, A., Takahashi, T., Kornkachuchai, R., Charoenkiatkul, S., Kishi, T., and Okamoto, T.: Protective effects of coenzyme Q10 on decreased oxidative stress resistance induced by simvastatin. *J. Clin. Biochem. Nutr.*, **40**, 194–202, 2007.

[16] Kishi, H., Nishii, S., Nishikawa, K., Maruta, E., and Hiraoka, E.: Clinical application of coenzyme Q10 and the quality control of its preparations in Japan. in *Biomedical and Clinical Aspects of Coenzyme Q*, Vol. 3, eds. By Folkers, K. and Yamamura, Y., Elsevier/North-Holland Biomedical Press, Amsterdam, pp. 45–50, 1981.

[17] Okamoto, T., Fukunaga, Y., Ida, Y., and Kishi, T.: Determination of reduced and total ubiquinones in biological materials by liquid chromatography with electrochemical detection. *J. Chromatogr.*, **430**, 11–19, 1988.

[18] Okamoto, T., Matsuya, T., Fukunaga, Y., Kishi, T., and Yamagami, T.: Human serum ubiquinol-10 levels and relationship to serum lipids. *Int. J. Vitam. Nutr. Res.*, **59**, 288–292, 1989.

[19] Takahashi, T., Shitashige, M., Okamoto, T., Kishi, T., and Goshima, K.: A novel ubiquinone reductase activity in rat cytosol. *FEBS Lett.*, **314**, 331–334, 1992.

[20] Takahashi, T., Yamaguchi, T., Shitashige, M., Okamoto, T., and Kishi, T.: Reduction of ubiquinone in membrane lipids by rat liver cytosol and its involvement in the cellular defense system against lipid peroxidation. *Biochem. J.*, **309**, 883–890, 1995.

[21] Kishi, T., Takahashi, T., Mizobuchi, S., Mori, K., and Okamoto, T.: Effect of dicumarol, a NAD(P)H:quinone acceptor oxidoreductase 1 (DT-diaphorase) inhibitor on ubiquinone redox cycling in cultured rat hepatocytes. *Free Radic. Res.*, **36**, 413–419, 2002.

[22] Beyer, R.E., Segura-Aguilar, J., Di Bernardo, S., Cavazzoni, M., Fato, R., Fiorentini, D., Galli, M.C., Setti, M., Landi, L., and Lenaz, G.: The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. *Proc. Natl. Acad. Sci. USA*, **93**, 2528–2532, 1996.

[23] Landi, L., Fiorentini, D., Galli, M.C., Segura-Aguilar, J., and Beyer, R.E.: DT-diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. *Free Radic. Biol. Med.*, **22**, 329–335, 1997.

[24] Xia, L., Nordan, T., Olsson, J.M., Damdimopoulos, A., Bjorkhem-Bergman, L., Nalvarte, I., Eriksson, L.C., Arner, E.S., Spyrou, G., and Bjornstedt, M.: The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. *J. Biol. Chem.*, **278**, 2141–2146, 2003.

[25] Olsson, J.M., Xia, L., Eriksson, L.C., and Bjornstedt, M.: Ubiquinone is reduced by lipoamide dehydrogenase and this reaction is potently stimulated by zinc. *FEBS Lett.*, **448**, 190–192, 1999.

[26] Xia, L., Bjornstedt, M., Nordman, T., Eriksson, L.C., and Olsson, J.M.: Reduction of ubiquinone by lipoamide dehydrogenase. An antioxidant regenerating pathway. *Eur. J. Biochem.*, **268**, 1486–1490, 2001.

[27] Yan, J., Fujii, K., Yao, J., Kishida, H., Hosoe, K., Sawashita, J., Takeda, T., Mori, M., and Higuchi, K.: Reduced coenzyme Q10 supplementation decelerates senescence in SAMP1 mice. *Exp. Gerontol.*, **41**, 130–140, 2006.